SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Nov 9 2009

SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.

SuperGen’s presentations will review clinical and non-clinical advances in the following compounds: MP-470, SGI-1776, SGI-110, SGI-1252, as well as two presentations on the Etk program. The posters will be made available for viewing on the company’s website www.supergen.com following the respective presentations.

Source:

http://www.supergen.com/

Posted in: Pharmaceutical News

Tags: , , ,

Comments (0)

Suggested Reading

Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels
MONET: New AI tool enhances medical imaging with deep learning and text analysis
New trials show promise for immune checkpoint blockers in early-stage lung cancer
New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact
Liver cells effectively serve as immune checkpoint regulating anti-cancer immunity
Study links air pollution to increased colorectal cancer risk through DNA changes
Breast cancer survivors at higher risk of developing second cancers
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes